In this model, TMBIM1 inhibited the occurrence of HCC, as evidenced by better liver condition, fewer tumor nodules and smaller sizes in the AAV8-Tmbim1 group at 10, 12 and 14 weeks (Fig. 2, D–F). Here, TMBIM1 is linked to hepatocellular carcinoma.